Treatment Options for urinary tract infections caused by extended-spectrum B-lactamase-producing Escherichia coli and Klebsiella pneumoniae by Salvatore, Dominick & Resman-Targoff, Beth
5/30/2018 Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pn…
https://www.printfriendly.com/p/g/4Vi2qT 1/5
January 5, 2015
Treatment Options for Urinary Tract Infections Caused by
Extended-Spectrum Β-Lactamase-Producing Escherichia
coli and Klebsiella pneumoniae
medicine2.missouri.edu/jahm/treatment-options-urinary-tract-infections-caused-extended-spectrum-β-lactamase-producing-
escherichia-coli-klebsiella-pneumoniae/
Dominick J. Salvatore Pharm D, BCPS  , Beth H. Resman-Targoff Pharm D
Division of Pharmacy Practice and Administration, University of Missouri – Kansas City, School of
Pharmacy at MU, Columbia, Missouri
 Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma Health
Sciences Center, College of Pharmacy, Oklahoma City, Oklahoma
Corresponding author:  Dominick Salvatore, Pharm.D., BCPS, University of Missouri – Kansas City
School of Pharmacy at MU, Division of Pharmacy Practice and Administration, 815 Lewis Hall,
Columbia, MO 65211, Telephone Number: (573) 884-7678, Fax Number: (573) 884-2166, Email:
SalvatoreD@umkc.edu
Citation: D J Salvatore, B H Resman-Targoff. Treatment Options for Urinary Tract Infections Caused
by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumonia. Journal of
Academic Hospital Medicine 2015, Volume 7, Issue 1
INTRODUCTION  
Increased utilization of antibiotics has contributed to greater resistance among pathogenic bacteria.
The prevalence of such organisms has created challenges for practitioners treating bacterial
infections. One of the most frequently encountered infections in both inpatient and outpatient
settings is urinary tract infections (UTIs). Escherichia coli is the most commonly isolated
uropathogen.  Both E. coli and Klebsiella pneumoniae, another uropathogen, are capable of
producing extended-spectrum β-lactamases (ESBL) which result in resistance to many antibiotics
that are typically used in the treatment of UTIs. An analysis of inpatient urinary isolates in the United
States found rates of ESBL-producing E. coli (ESBL-EC) and K. pneumoniae (ESBL-KP) to be 6.8% and
10.3%, respectively.
ANTIBIOTICS REVIEW
Carbapenems are considered the most reliable treatment for infections caused by ESBL-producing
bacteria.  Despite their utility, resistance has emerged, placing a focus on finding alternative
antibiotics for UTIs so that carbapenems can be reserved for more serious infections.
Antimicrobials that may prove useful for this purpose include nitrofurantoin, fosfomycin, amikacin,
cefepime, and piperacillin/tazobactam. These non-carbapenem treatment options for UTIs caused
by ESBL-EC and ESBL-KP will be reviewed.
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Nitrofurantoin, a commonly used oral agent for cystitis treatment, possesses activity against E. coli,
but it is not reliably active against K. pneumoniae.  Tasbakan et al. conducted a retrospective study
of the efficacy of nitrofurantoin for the treatment of ESBL-EC cystitis.  All isolates were susceptible
to nitrofurantoin. The study included 75 patients who did not have fever or leukocytosis, but 81% of
whom had complicated urinary tract infections. All patients received nitrofurantoin (macrocrystals)
50 mg every 6 hours for 14 days. Symptom resolution occurred in 69% of patients and follow-up
cultures obtained 7-9 days after treatment completion were negative in 68%. Despite the use of the
extended treatment duration, the rate of success observed was limited, but suggests a potential
alternative therapy.
Fosfomycin is another oral agent with potential for treatment of cystitis caused by ESBL-producing
microorganisms.  It possesses in-vitro activity against both ESBL-EC (97% susceptible) and, to a
lesser degree, ESBL-KP (81% susceptible).  Pullukcu et al. conducted a retrospective cohort study of
52 patients to evaluate the efficacy of fosfomycin in the treatment of susceptible ESBL-EC cystitis.
All included patients were afebrile and had a normal white blood cell count prior to initiation of
therapy. The majority of the patients had complicated cystitis (69%). All patients received
fosfomycin 3 g every 48 hours for a total of 3 doses. Pre-treatment symptoms resolved in 94% of
patients at 7-9 days after the completion of treatment and 79% of patients had negative repeat
urine cultures at that time. These results were consistent with those found by Rodriguez-Baño et al.
who evaluated patients with cystitis caused by ESBL-EC.  That study found that 93% (26/28) of
patients treated with a single 3 g dose of fosfomycin had resolution of their pre-treatment
symptoms without recurrence for 4 weeks. Fosfomycin can be considered for cystitis caused by
ESBL-EC, but its utility against ESBL-KP has not been established.
There is limited evidence supporting the use of amikacin in UTIs caused by ESBL-producing
bacteria, but in vitro susceptibility to amikacin was reported to be 89% for ESBL-EC and 59% for
ESBL-KP.  Amikacin monotherapy is effective for the treatment of cystitis and pyelonephritis caused
by non-ESBL-producing bacteria.  In a pooled analysis of 3 prospective, multicenter, randomized
controlled trials, 93% (51/55) of patients treated for uncomplicated or complicated UTIs with
amikacin 7.5 mg/kg twice daily achieved microbiologic success. All bacterial isolates included in this
evaluation were susceptible to amikacin. A benefit of amikacin is that high urinary concentrations
are achieved since 94-98% of unchanged drug is recovered in the urine at 24 hours.
There has been much debate over the utility of cefepime for infections caused by ESBL-producing
bacteria. Compared to the previously discussed agents, urinary isolates of ESBL-EC and ESBL-KP are
far less susceptible to cefepime, 22.5% and 33.4% respectively.  Also, much of the evidence
evaluating cefepime use for ESBL-producing organisms has focused on patients with bacteremia.
The findings from these studies suggest that lower MICs (≤ 1 mcg/mL) and possibly higher
cefepime doses are associated with favorable outcomes.  Of note, a retrospective chart review
described 3 patients who were successfully treated with cefepime for UTIs caused by ESBL-
producing Enterobacteriaceae (1 ESBL-EC and 2 ESBL-KP).  All isolates had a cefepime MIC ≤ 1
mcg/mL. Cefepime is primarily excreted unchanged, so high concentrations are achieved in the
urine.  Given these findings and the new lower breakpoints established by Clinical and Laboratory
Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, cefepime may
prove to be a valuable treatment option for UTIs when the pathogen is susceptible.
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Another treatment option for ESBL-EC and ESBL-KP UTIs is piperacillin/tazobactam. Bouchillon et al.
showed piperacillin/tazobactam susceptibility among urinary isolates from hospitalized patients in
the United States to be 81.7% for ESBL-EC and 31.3% for ESBL-KP.  Piperacillin/tazobactam is also
largely eliminated renally, with 68% of piperacillin and 80% of tazobactam excreted in the urine as
unchanged drug.  Although there is a paucity of data for the use of piperacillin/tazobactam for
UTIs caused by ESBL-producing bacteria, the evidence appears favorable.  Two small studies (6 and
14 patients) reported 100% treatment success with the use of piperacillin/tazobactam for UTIs (type
of ESBL-producing organisms not specified).  Based on these limited results,
piperacillin/tazobactam may have utility for these infections.
IN PIPELINE
In addition to the antibiotics discussed, there are a few new combinations in development that have
potential to be very efficacious for ESBL-EC and ESBL-KP UTIs. One is ceftazidime/avibactam, which
has shown a high degree of in vitro activity against these pathogens. It is important for
providers to be aware of the evidence for antibiotic use for UTIs caused by ESBL-producing bacteria.
Understanding of these agents can help healthcare practitioners be better stewards of antibiotic
usage and hopefully lessen the burden of carbapenem resistance.
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